Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash & Equivalents (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Cash & Equivalents for 11 consecutive years, with $213.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $213.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $213.2 million, a N/A change, with the full-year FY2025 number at $213.2 million, changed N/A from a year prior.
  • Cash & Equivalents was $213.2 million for Q4 2025 at Crescent Biopharma, up from $133.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $213.2 million in Q4 2025 to a low of $5.6 million in Q1 2025.
  • A 5-year average of $73.0 million and a median of $59.1 million in 2022 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 825.45% in 2025; the steepest drop was 82.11% in 2025.
  • Crescent Biopharma's Cash & Equivalents stood at $90.3 million in 2021, then plummeted by 46.96% to $47.9 million in 2022, then decreased by 12.7% to $41.8 million in 2023, then crashed by 65.54% to $14.4 million in 2024, then skyrocketed by 1380.56% to $213.2 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Cash & Equivalents are $213.2 million (Q4 2025), $133.3 million (Q3 2025), and $5.6 million (Q1 2025).